Immuno-Oncology Conference, London – Agenda Released for SMi's Inaugural Event

London, United Kingdom, April 30, 2018 --(PR.com)-- The fast-paced field of Immuno-Oncology has a massive potential to deliver successful and durable cancer therapies.

SMi's Immuno-Oncology Conference (26 – 27 September 2018, London, UK) will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

The event will offer programme with over 15 engaging presentations, case studies and keynote addresses, including:
· Targeting immune checkpoints with Humabody VH therapeutics
· Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy
· Tumour mutation burden and the potential of its use as an indication of treatment choice
· Unwanted immunogenicity and functionality testing of immuno-oncology drugs
· New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology

Over 15 leading experts in Immuno-Oncology will be presenting at the event, including:
· James Legg, Vice President R&D, Crescendo Biologics
· Andrew Exley, Medical Assessor, MHRA
· Harry Smith, Medical Scientist, Gilead Sciences
· Grace Macaulay, Global Safety Physician Patient Safety Oncology, MedImmune
· David Giljohan, CEO, Exicure
· Kandeepan Ganeshalingam, Executive Director, Oncology Therapeutic Area Head, European Clinical Development, MSD
· Rochana Wickramasinghe, Director of Oncology Evaluation, AstraZeneca

Two pre-conference workshops, on 25th September 2018:
· Strategic competitive intelligence in the immuno-oncology space - hosted by LucidQuest Ventures
· Could the microbiome boost cancer immuno-therapy - hosted by ImmuneBiotech and Lund University

Follow event updates to be in the know about who will be joining the conversation.

Further details on http://www.immuno-oncology-conference.com/prcom

Twitter - @SMIpharm & #immunooncologysmi
LinkedIn - SMi Pharma

Contact:
+44 (0)20 7827 6000
ldurneva@smi-online.co.uk